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Designing services with the capacity and expertise to meet the needs of the chronic
hepatitis C (CHC) population in the era of direct acting antivirals (DAAs), and widening
access to such treatments, requires detailed understanding of the characteristics and
healthcare needs of the existing patient population. In this retrospective analysis of data
from theNational HCV ResearchUKBiobank betweenMarch 2012 andOctober 2014,
the characteristics of the CHCpopulation currently under specialist care in theUKwere
evaluated—with specific focus upon use of medications, adverse lifestyle choices, and
comorbidities. Demographic data, risk factors for CHC acquisition, HCV genotype, liver
disease status, lifestyle factors, comorbidities, and medication classes were collected.
Data were analyzed by history of injecting drug use (IDU), age, and severity of liver
disease. A total of 6278 patients (70.5% white; median age, 52 years) from 59 UK
specialist centreswere included; 59.1% of patients had acquiredHCV through IDU. The
prevalence of adverse lifestyle factors was significantly lower in non-IDU compared
with previous IDU or recent IDU patients. Depression was common in the previous
(50.8%) and recent IDU (68.1%) groups, compared with 27.6% in non-IDU patients.
Cirrhosis was common (23.6%), and prevalence increased with age. We describe a
heterogeneous, polymorbid, and aging population of CHC patients in secondary care,
anddemonstrate underrepresentation of injecting druguserswithin the current system.
The implications of this present significant challenges to physicians and healthcare
commissioners in designing services which are fit for purpose inthe DAA era.
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1 | BACKGROUND
Chronic hepatitis C (CHC) is estimated to affect approximately 130-150
million people worldwide, causing around 500 000 liver-related deaths
per year.1 In 2013/2014, approximately 214 000 individuals had CHC in
the UK. Between 1996 and 2012, deaths from end-stage liver disease or
hepatocellular carcinoma where hepatitis C was mentioned on the death
certificate more than tripled in the UK.2 In 2012 in the UK, approximately
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in
any medium, provided the original work is properly cited and is not used for commercial purposes.
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3% of patients diagnosed with CHC received CHC treatment, a figure
which is thought to be lower among people who inject drugs (PWID).3
In the UK, 90% of individuals infected with hepatitis C virus (HCV)
are thought to have acquired the infection through injecting drug use
(IDU), and approximately 50% of PWID are estimated to have CHC.4
Data from Public Health England demonstrate that rapid upscaling of
treatmentwith new therapies is required if further rises in severe CHC-
related disease are to be prevented.5
The introductionof interferon-freedirect-actingantivirals (DAAs)has
changed the CHC treatment paradigm.6,7 Compared to interferon-based
regimens, treatment with DAAs is more efficacious, better tolerated, and
of shorter duration.8 While there was previously no available therapy for
CHCwith advanced liver disease, recent data show effectiveness of DAA
therapy in thispopulation: inanobservationalcohort studyof467patients
in theUK,ofwhom409haddecompensatedcirrhosis,DAAtherapy led to
viral clearance in 81.6% of patients.9 Sustained virological response was
associatedwith improvements in liver functionwithin6monthscompared
with an untreated, matched control group.
Studies suggest that, compared with individuals without HCV
infection,patientswithCHChaveahigherburdenof comorbidities (such
as psychiatric disorders, co-infection with hepatitis B and/or HIV,
atherosclerosis, and chronic kidney disease) in addition to a high
prevalence of adverse lifestyle choices such as alcohol and substance
abuse.10,11 Such factors may pose challenges to effective treatment,
particularly for patients who have acquired HCV through IDU.12,13
Almost all current DAAs are associated with risks of drug-drug
interactions (DDIs), although thesediffer substantially betweenagents.6
Unlike in HIV, where there is a live national dataset for all patients
enrolled in treatment (The HIV and AIDS Reporting System; https://
www.gov.uk/guidance/hiv-surveillance-systems), very little is known
about the make-up of the UK CHC patient population currently in
secondary care—for whom services and treatments will need to be
designed and appropriately prioritized in the DAA era. The absence of
such information leaves vital clinical, commissioning, and public health
questions unanswered. These include how clinical services should be
structured to address the specific healthcare needs of the population
requiring treatment, the extent of the future resource requirement, the
expertise required to provide such care (both in terms of disease
management and in laboratory services), and the associated cost
implications of this. From a public health perspective, it is unclear
whether the population currently enrolled in secondary care services,
and therefore those towhomDAAswill beavailable, reflect thewiderUK
HCVpopulation and, if not, howefforts toprovidemoreequitable access
to care should be focused. Understanding the characteristics and wider
health needs of the UKCHCpopulation currently in secondary care, and
how this reflects wider population estimates, is essential in this regard.
Furthermore, anappreciationof the factors specifically affectingPWIDis
vital in widening access to care in this already disadvantaged group.
The aim of this studywas to use patient data from theNationalHCV
ResearchUKBiobank todescribe thedemographics ofpatients currently
under specialist hepatology care in theUKwhoare likely tobeeligible for
DAA treatment over the next 5 years, and investigate the prevalence of
comorbidities, adverse lifestyle factors, and use of medications with
potential DDIs involving DAAs. This is with a view to estimating clinical
need, informing future service design, and directing public health
interventions. The characteristicsofpatientswhoacquiredHCVthrough
IDU and non-IDU transmission routes were also compared.
2 | PATIENTS AND METHODS
This was a retrospective analysis of patient data from centres enrolled
in the National HCV Research UK Biobank (http://hcvresearchuk.org).
HCV Research UK is a national cohort of over 10 000 patients with
HCV infection recruited from59 secondary care clinics across England,
Scotland, and Wales. Eligibility criteria for enrolment in the database
were attendance at a secondary care clinic for management of chronic
HCV infection and ability to give informed consent.
Inclusion criteria in this analysiswereCHCpatients enrolled inHCV
ResearchUK from2012 onwards, aged over 18 years, infectedwith any
HCV genotype, viraemic at enrolment, and not receiving a course of
CHC treatment at enrolment. Excludedpatients included thosewhohad
cleared CHC or were on treatment. This represents the population who
will be currently under consideration for DAA treatment within the UK.
Data fromMarch 2012 toOctober 2014were collected from fixed
text data fields which comprised demographic data; risk factors for
CHC acquisition (collected hierarchically in the following order: IDU,
blood/blood product transfusion, born abroad, sexual partner with
HCV, perinatal exposure, other [mostly exposure through tattoo
needles, body piercing, other needle exposure]); HCV genotype; liver
disease status; lifestyle factors (tobacco smoking, cannabis use, and
alcohol use); comorbidities (renal failure requiring dialysis, diabetes,
cancer, depression [defined as a positive answer to any of the following
queries: ever diagnosed with clinical depression, ever treated for
depression, ever admitted to hospital for depression, ever attempted
suicide], HIV co-infection, bleeding disorder, and cryoglobulinaemia);
and history of medication with classes of medications with known DDI
potential to DAAs (antidiabetics, antidepressants, antiretrovirals,
hypnotics, opiate substitution therapy, steroids, other immunosup-
pressives, statins). Antidepressants, opioids, and hypnotics were
grouped collectively as psychotropic agents. For patients who had
acquired HCV through IDU, patients were further categorized
according to drug use at the time of enrolment. Patients who had
injected within the last 6 months or who were requiring opioid
replacement therapy at the time of enrolment were classified as
“recent IDU.” Patients who had acquired CHC through previous
intravenous drug use, but who had not injected within the last
6months andwere currently not requiring opioid replacement therapy
were classified as “previous IDU.”
Logistic regression was used to determine differences in lifestyle
factors, comorbidities, and medication use according to the method of
HCV acquisition. Non-IDU patients were used as the reference group,
with odds ratios and 95% confidence intervals determined for the
previous IDUand recent IDUgroups separately.Odds ratiosover1 relate
to a higher likelihood of the lifestyle factor/comorbidity/medication in
the previous or current IDU group than in the reference non-IDU group.
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Univariable logistic regression was performed initially, then odds ratios
were adjusted for age to account for differences between acquisition
routes. Where indicated, proportions were age-standardized by direct
standardization, using the non-IDU group as the reference. Statistical
analysis was carried out using Stata 13.1 (StatCorp, Austin, TX).
3 | RESULTS
A total of 6278 patients with CHC from 59 UK specialist centres were
included in the analysis. Patient demographics are shown in Table 1.
Over two-thirds (70.5%) of patients were male, and 85% were white.
Overall, 58% of patients were aged 50 years or above; median age was
52 (interquartile range 43-59) years. Overall, 59.1% of patients had
acquired CHC through IDU (Fig. S1). The median age of patients who
acquired HCV through IDU was 50 years (interquartile range 42-56)
compared with 55 years (interquartile range 46-62) in non-IDU
patients. The mean age of the IDU group was significantly lower than
the non-IDU group (49.2 vs 54.0, P < 0.0001). In total, 50% of patients
were infected with HCV genotype 1, and 33.7% were infected with
genotype 3. The distribution of patients by genotype was broadly
similar in IDU and non-IDU acquisition groups.
The severity of liver disease at enrolment was recorded by the
treating clinician and classified as non-cirrhotic, cirrhosis, or
decompensated cirrhosis. The overall prevalence of cirrhosis (com-
pensated and decompensated) was 23.6% across the whole cohort, a
figure that was not significantly different between etiological groups.
The prevalence of cirrhosis rose sharply with age, with 36.6% of those
over 60 years of age having cirrhosis or decompensated cirrhosis.
Table 2 shows the prevalence of adverse lifestyle factors. After
adjusting for age, the prevalence of all adverse lifestyle factors were
significantly higher in patients with previous and recent IDU compared
with non-IDU patients. The prevalence of all adverse lifestyle factors
other than current alcohol usewere significantly higher in patientswith
recent IDU compared with non-IDU patients.
Table 3 shows prevalence of comorbidities. The most common
comorbidities were depression (26.1%), diabetes (11.3%), and
malignancy (not including hepatocellular carcinoma [HCC]) (5.0%).
HIV co-infection was present in 5.0% of patients. Compared with
patients who had not acquired HCV through IDU (after adjusting for
age), depression was significantly more common among patients with
previous or recent IDU, while diabetes and renal failure were
significantly less common. After age adjustment, malignancy and
HIV were significantly less common among patients with recent IDU
compared with non-IDU (1.5% and 4.1% vs 6.7% and 5.5%,
respectively).
Figure 1 shows that the prevalence of diabetes, malignancy, and
renal failure increased with age, reaching 22.9%, 18.1%, and 2.2%,
TABLE 1 Patient demographics
n (%)
Total, N = 6278 HCV acquired via IDU, N = 3714 HCV acquired via route other than IDU, N = 2564
Male 4424 (70.5) 2815 (75.8) 1527 (62.2)
White 5315 (84.7) 3550 (95.6) 1674 (68.2)
Median age (IQR), years 52 (43-59) 50 (42-56) 55 (46-62)
Age, years
18-29 165 (2.6) 92 (2.5) 71 (2.9)
30-39 861 (13.7) 564 (15.2) 283 (11.5)
40-49 1613 (25.7) 1149 (31.0) 446 (18.2)
50-59 2156 (34.3) 1296 (34.9) 823 (33.5)
60-69 1176 (18.7) 574 (15.5) 574 (23.4)
≥70 294 (4.7) 32 (0.9) 254 (10.3)
Unknown 13 (0.2) 7 (0.2) 5 (0.2)
Genotype
1 3141 (50.0) 1908 (51.4) 1184 (48.2)
2 250 (4.0) 147 (3.96) 99 (4.03)
3 2115 (33.7) 1291 (34.8) 792 (32.3)
4 225 (3.6) 58 (1.6) 163 (6.6)
5 15 (0.2) 1 (0.03) 13 (0.53)
6 8 (0.1) 3 (0.08) 3 (0.12)
Other 23 (0.37) 19 (0.51) 4 (0.16)
Unknown 501 (8.0) 287 (7.73) 198 (8.06)
IDU, injecting drug use; IQR, interquartile range; HCV, hepatitis C virus.
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respectively in patients aged 60 years and above. Depression was the
only pathology that became less common with advancing age.
Overall, the most common medications with DDI potential were
psychotropic agents (antidepressants, opioids, and hypnotics)
(38.6%), antidiabetics (9.3%), immunosuppressants (6.1%), statins
(4.9%), and antiretrovirals (4.9%). Table 4 shows the prevalence of
prescribed medications. Compared with the non-IDU group, the use
of psychotropic agents was significantly more common in previous
and recent IDU groups. Among patients with current IDU, 48% were
prescribed antidepressants and/or hypnotic combined, of which
80% were antidepressants alone. Use of antidiabetics was
significantly lower in previous IDU and recent IDU patients
compared with non-IDU patients. Use of immunosuppressants,
antiretrovirals, and statins was significantly lower in patients with
recent IDU versus non-IDU. The relatively high proportion of
patients on immunosuppressants, particularly in the non-IDU group,
may be reflective of the proportion of the cohort who had
undergone orthotopic liver transplantation (OLT). 5.2% of the
cohort (9.3% of non-IDU group, 4.3% of previous IDU group, 0.2%
of recent IDU group) were recorded as having undergone OLT prior
to treatment. OLT was recorded as a free text field (as opposed to a
compulsory fixed text field), so these figures may represent an
underestimate.
Figure 2 shows the prevalence of medication use by age. Use of
antidiabetics, immunosuppressants, and statins increased with age
(18.8%, 12.7%, and 11.7%, respectively, in patients over 60 years of
age). Use of psychotropicmedication demonstrated the opposite trend
with frequency of use decreasing with age.
Supplementary Table S1 shows the frequencies of common co-
medications relating to stage of liver disease. The increased rates of
antidiabetic medications among cirrhotic patients may reflect the
significance of diabetes as a risk factor for the development of
cirrhosis. Immunosuppressant usage is likely to reflect rates of liver
transplantation, with increased use in patients with non-cirrhotic
TABLE 2 Alcohol consumption, current tobacco, and cannabis use, by IDU status (non-IDU, previous IDU, and recent IDU)
Non-IDU (ref),
n = 2456 Previous IDU, n = 2256 Recent IDU, n = 1458









Current alcohol use 843 (34.3) 1036 (45.9) 1.6 (1.4, 1.8) 1.6 (1.4, 1.8) 594
(40.7)
1.3 (1.1, 1.5) 1.2 (1.0, 1.4)
History of high alcohol
consumption
496 (20.2) 1165 (51.6) 4.0 (3.5, 4.5) 4.0 (3.6, 4.6) 696
(47.7)
3.4 (3.0, 3.9) 3.6 (3.1, 4.2)






Current cannabis use 223 (9.1) 640 (28.4) 3.9 (3.3, 4.6) 3.8 (3.2, 4.5) 667
(45.7)
8.3 (7.0, 9.8) 7.4 (6.2, 8.8)
CI, confidence interval; IDU, injecting drug use; OR, odds ratio. The non-IDU groupwas used as the reference groupwhen calculating the unadjusted (unadj.)
and age-adjusted (age-adj.) ORs.
TABLE 3 Prevalence of comorbidities by IDU status (non-IDU, previous IDU, and recent IDU)
Non-IDU (ref)
n = 2456 Previous IDU, n = 2256 Recent IDU, n = 1458









History of depression 679 (27.6) 1145 (50.8) 2.3 (2.0, 2.6) 2.3 (2.0, 2.6) 993
(68.1)
3.4 (2.9, 3.9) 3.4 (2.9, 3.9)
Diabetes 437 (17.8) 208 (9.2) 0.5 (0.4, 0.6) 0.6 (0.5, 0.7) 51
(3.5)
0.2 (0.1, 0.2) 0.3 (0.2, 0.4)
Malignancy (not
including HCC)
176 (6.7) 118 (5.23) 0.7 (0.6, 0.9) 0.9 (0.7, 1.1) 22
(1.5)
0.2 (0.1, 0.3) 0.4 (0.2, 0.6)
HIV 135 (5.5) 109 (4.8) 0.9 (0.7, 1.1) 0.8 (0.6, 1.1) 60
(4.1)
0.7 (0.5, 1.0) 0.6 (0.4, 0.8)
Renal failure 58 (2.4) 15 (0.7) 0.3 (0.2, 0.5) 0.3 (0.2, 0.5) 6 (0.4) 0.2 (0.1, 0.4) 0.2 (0.1, 0.5)
CI, confidence interval; HCC, hepatocellular carcinoma; HIV, human immunodeficiency virus; IDU, injecting drug use; OR, odds ratio. The non-IDU groupwas
used as the reference group when calculating the unadjusted and age-adjusted ORs.
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grafts, and smaller numbers of patients with concomitant graft
cirrhosis requiring ongoing immunosuppression.
4 | DISCUSSION
This study represents the first description of patterns of non-HCV
comorbidities, co-medications with DDI potential, and lifestyle factors in
patientswithCHCwhoareorwill be eligible forDAA treatment in theUK.
Comorbidities were common in the overall cohort, particularly
depression (26.1%), diabetes (11.3%), and non-hepatic malignancy
(5.0%). Use of medications with potential DDIs involving DAAs were
also widespread, with psychotropic medications (38.6%), antidiabetics
(9.3%), immunosuppressants (6.1%), statins (4.9%), and antiretrovirals
(4.9%) being the most commonly recorded agents.
In this cohort, 59.1% of patients had acquired HCV through IDU,
and 23% were recent injectors. In the UK it is estimated 90% of
individuals infected with HCV are thought to have acquired the
infection through IDU and approximately 50% of PWID have CHC.4 As
such the number of PWID in this cohort appears disproportionately
low, indicating it is likely that PWID are significantly under-
represented in secondary care. This may reflect inequity in access to
treatment for these patients under the traditional service model.3
Although NICE guidelines were changed in 2004 to include current
injectors,14 there is evidence that some hospitals still use this as a
criterion for exclusion from treatment.3
Aside from the ethical responsibility to deliver services which equate
to need—there are further public health benefits of focussing service
delivery strategies around this group. A recent modelling analysis by
Martin et al15 suggested that the treatment of active injectors is an
effective measure for decreasing HCV infection in a community by
reducing the pool of patients capable of passing the infection onto others.
At present access to DAA treatment within the NHS is dependent
upon enrolment in a secondary care clinic, and our results demonstrate
this model of care is unlikely to be fit for purpose in providing
appropriate access to the IDU community. The Scottish Hepatitis C
Action Plan,which specifically targets PWID and ensures those infected
receive rapidandoptimal treatment, is anexampleofhowservice design
could be revisited in order to redress this inequity. Initiatives ranged
from the introduction of testing in specialist drug services through
finger-prick blood sampling by non-clinical staff, to the setting of
government targets to ensure rapid scale-up of antiviral therapy.16
In addition to the problems with accessing PWID, our data
demonstrates this population may be particularly challenging to treat,
given the levels of comorbidities and use of medications with potential
DDIs. Prevalenceofhazardous lifestyle factors, such as smoking, alcohol
abuse, andcannabis use,were significantly higher in previous and recent
IDU patients compared with the non-IDU group. Mental illness was
extremely common in the IDU cohorts, reflected by the high prevalence
of depression and use of psychotropic medication (the latter may be an
indicator of additional, uncaptured, recreational drug use).
Conversely, age adjusted use of other medication classes by
current injectors was significantly lower compared with non-IDU
patients (Table 4), a trend that was mirrored when looking at
prevalence of physical comorbidities. Whereas differences observed
in psychiatric co-morbidity were largely expected, the opposite trend
FIGURE 1 Prevalence of comorbidities by age group. HCC,
hepatocellular carcinoma; HIV, human immunodeficiency virus
TABLE 4 Prevalence of medication with DDI potential by IDU status (non-IDU, previous IDU, and recent IDU)
Non-IDU (ref)
n = 2456 Previous IDU, n = 2256 Recent IDU, n = 1458















Antidiabetics 375 (15.3) 157 (7.0) 0.4 (0.3, 0.5) 0.5 (0.4, 0.6) 40 (2.7) 0.2 (0.1, 0.2) 0.3 (0.2, 0.4)
Immuno-
suppressants
217 (8.8) 136 (6.0) 0.7 (0.5, 0.8) 0.8 (0.6, 1.0) 15 (1.0) 0.1 (0.1, 0.2) 0.2 (0.1, 0.3)
Antiretrovirals 130 (5.4) 110 (4.9) 0.9 (0.7, 1.2) 0.9 (0.7, 1.1) 59 (4.0) 0.7 (0.5, 1.0) 0.7 (0.5, 0.9)
Statins 165 (6.7) 96 (4.3) 0.7 (0.5, 0.9) 0.9 (0.7, 1.2) 39 (2.7) 0.3 (0.2, 0.4) 0.6 (0.4, 0.9)
CI, confidence interval; DDI, drug-drug interaction; IDU, injecting drug user; OR, odds ratio. The non-IDU group was used as the reference group when
calculating the unadjusted (unadj.) and age-adjusted (age-adj.) ORs.
aPsychotropics include antidepressants, opioids, and hypnotics.
bDefinition of recent IDU included those on opioid substitution therapy. Opioids were also classified as a psychotropic agent in this calculation, partly
accounting for high odds ratio here. Odds ratios removing opioids from definition of psychotropic agents: Unadjusted: Previous IDU: 2.0 (CI 1.8-2.3) Recent
IDU: 4.8 (CI 4.2-5.6) Age adjusted: Previous IDU: 2.0 (CI 1.8-2.3) Recent IDU: 4.9 (CI 4.2-5.7).
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with physical co-morbidity was unexpected. Several possible explan-
ations for this exist, the first relating to potential differences in health
seeking behaviors between the groups. Data were recorded at the
point of enrolment in secondary care. Given the commonly circuitous
and limited access to healthcare amongst IDU communities described
above, it is plausible that the physical co-morbidities would have been
under-diagnosed or reported at the point of enrolment, and as such not
captured in the data. Characteristics (in terms of social support, access
to healthcare, etc) of PWIDenrolled in secondary caremay be different
to an otherwise matched population not enrolled in secondary care.
Given the under-representation of PWID in this secondary care
cohort, it is unlikely that reported levels of co-morbidity accurately
reflect those of the wider IDUHCV population. Conversely, character-
istics of the non-IDU group are likely to be more representative. IDU
groupswere significantly younger, and therefore less likely to have age
related co-morbidities, such as type 2 diabetes and hypercholester-
olaemia. Statistical adjustment for age was undertaken, with rates of
comorbidity significantly lower following adjustment, but not before.
While we consider this adjusted comparison more appropriate, it
assumes a linear effect of increasing age which has the potential to
overstate differences. Recorded OLT was significantly more common
within the non-IDU group (9.3% non-IDU vs 2.7%—IDU overall).
Metabolic syndrome increases dramatically following OLT,17 and the
substantially higher rates of OLT amongst non-IDU patients may have
contributed to the higher rates of statin and anti-diabetic use in this
group. It is likely that complications from cirrhosis are commonly
replaced by complications of the metabolic syndrome among patients
who undergo OLT prior to treatment—a factor which impacts
disproportionately on the non-IDU group in this analysis.
In the current study population, 23.6% of patients in this cohort had
cirrhosis. Although advanced liver disease in patients with CHC has
previously been a barrier to effective CHC treatment, the safety and
clinical efficacy of DAAs in patients with decompensated cirrhosis has
been widely demonstrated.9 Patients with advanced liver disease
nonetheless represent a vulnerable group who are likely to require
more prolonged and complex treatments, will be more susceptible to
adverse events, and in whom the potential effects of DDI may be more
severe. Rates of cirrhosis increased sharply with age. The proportion of
patients commencing treatment with cirrhosis is therefore also likely to
increase in linewith the projected increases in age of the CHC population
under treatmentover thenextdecade.Thishasservicedesign implications
beyond HCV treatment itself, in that expertise in the management of
decompensated cirrhosis will need to be integrated within service design
—an important point of consideration, particularly in areas where HCV
treatment is co-ordinated by infectious disease physicians as opposed to
hepatologists, or when considering the allocation of specialist physician
time when designing nurse, or community centred services.
The results of our study concur with the high rates of comorbidities
and use of medications with DDI potential to DAAs reported among
patients with CHC in studies conducted in predominantly specialist
settings in theUSA18,19 andGermany.20Our study complements a recent
analysisofpatientswithCHCseen inUKprimarycare.21 In this studyover
two-thirdsofpatients receivedmedicationwithapotentialDDI toat least
one DAA, but less than 1% of patients received medications with
contraindications to all four DAAs studied. High levels of comorbidity
were also reported, with similar age-related trends as observed in the
current study. Both studies concur that patientswithCHC in theUKhave
high levels of non-HCV comorbidity and polypharmacy.
Thedatausedfor thisanalysiswereobtainedfromanopt-indatabase:
only those data added by clinicianswere available, and clinical noteswere
not accessible, creating a risk of information bias. While the cohort
analyzed in this study may not be reflective of the CHC population as a
whole, we consider it representative of CHC patients attending UK
secondary care, owing to the wide geographic range covered and the
types of clinics that participated. Indeed, in the largest centres, 100% of
patients were recruited. Lastly our analysis only includes data from
patients within secondary care services. A comparison with untreated
hepatitis C patients outside of secondary care services may better
highlightgaps incurrentaccess to treatment.Furthermore, thismaybetter
describe the demographics of the IDU population, and provide further
insight into how strategies to improve access should be targeted.
Our study demonstrates that the current population of patients with
CHCseen inUKsecondarycareconstitutesacomplexandheterogeneous
group at high risk of disease-drug and drug-drug interactions, both of
which can have damaging consequences for the patient and limit
effectivenessof therapy.Wedemonstrate thatPWIDarecurrentlyunder-
represented in secondary care clinics, and that this group is dispropor-
tionately affectedby concomitant burdensof adverse lifestyle factors and
mental illness, both ofwhichmay further limit effectiveness of treatment.
Upscaling CHC treatment and widening of access to care has the
potential to reduce population prevalence and ultimately deaths from
CHC-related end-stage liver disease. For this to be achieved, current
service models will need be re-evaluated, taking into account the
current inequitable access to PWID, and the necessary physician
expertise required to manage this complex and comorbid population.
Careful consideration of the clinical and cost implications will be
required by providers and payors.
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